Skip to main content
. 2022 Dec 4;197(3):503–513. doi: 10.1007/s10549-022-06775-1

Fig. 2.

Fig. 2

Investigator-assessed PFS in a the intention-to-treat population and b subgroups. CI confidence interval, D docetaxel, ECOG PS Eastern Cooperative Oncology Group Performance Status, ER estrogen receptor, FISH fluorescence in situ hybridization, H trastuzumab, HER2 human epidermal growth factor receptor 2, HR hazard ratio, IHC immunohistochemistry, P pertuzumab, PFS, progression-free survival, PgR progesterone receptor, Pla placebo